Filing Summary
Important identity note: The provided filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc. Investors should verify that this is the intended filing before relying on the information.
Business Context and Reporting Period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2014, filed November 14, 2014. Zeta Acquisition Corp. III was a Delaware development-stage, blank-check and shell company formed to identify and complete a business combination. It had no operating business, generated no revenue since inception, and had not identified or entered into discussions with a target company.
The company reported 5,000,000 common shares outstanding as of November 14, 2014.
Financial Position and Results
| Metric | Three Months Ended September 30, 2014 | Nine Months Ended September 30, 2014 | Comparable 2013 Period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| General and administrative expense | $4,764 | $14,145 | $14,647 for nine months |
| Interest expense | $1,664 | $4,936 | $1,664 for three months; $4,214 for nine months |
| Net loss | $6,428 | $19,081 | $6,139 for three months; $18,861 for nine months |
| Net loss per share | $0.00 | $0.00 | $0.00 |
| Operating cash flow | Not separately provided | $(3,351) | $(19,222) |
| Financing cash flow | Not separately provided | $15,000 | $25,000 |
At September 30, 2014, cash and cash equivalents were $18,217, compared with $6,568 at December 31, 2013. Current liabilities were $161,255 versus $133,025 at year-end 2013, including $125,000 of notes payable to stockholders and $22,111 of accrued interest. Stockholders’ deficit was $143,038, compared with $123,957 at December 31, 2013.
The company had no material investing cash flows, no reported margins because it had no revenue, and no material off-balance-sheet arrangements. The filing does not identify conventional bank debt; outstanding financing consisted primarily of unsecured, 6% stockholder notes due on demand.
Material Changes Versus Prior Comparable Period
- Nine-month net loss increased modestly to $19,081 from $18,861, primarily because interest expense rose to $4,936 from $4,214.
- Nine-month general and administrative expense decreased to $14,145 from $14,647.
- Operating cash use improved substantially to $3,351 from $19,222, while stockholder financing declined to $15,000 from $25,000.
- Cash increased by $11,649 during the first nine months, but this increase was driven by stockholder loans rather than operating activity.
- Current liabilities increased by $28,230 from December 31, 2013, while cash and other current assets increased by only $9,149.
Outlook, Risks, Contingencies, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC filings and acquisition investigations. It expected to fund those costs from existing cash, deferred service-provider fees, and additional loans or investments from stockholders, management, or other investors.
Management disclosed substantial going-concern uncertainty. The company had no revenue-generating operations, limited cash, significant liabilities relative to its assets, and dependence on related-party financing. Management stated that it could not assure that sufficient funding would be available for at least the next twelve months or that a suitable business combination would be completed.
- There was no assurance of additional financing or completion of a reverse merger or other business combination.
- Any eventual target could be financially unstable, early-stage, or operating in a high-risk industry.
- The company expected its limited resources would likely permit only one business combination, creating concentration and dilution risks.
- Accrued stockholder interest and demand notes represented material obligations that could require repayment when demanded.
- A valuation allowance fully offset approximately $65,600 of deferred tax assets because future realization was uncertain.
- The company had no material pending legal proceedings and reported no defaults or unregistered equity sales during the period.
- The company had not early adopted ASU 2014-10, which eliminates development-stage-entity reporting requirements for applicable periods.
Key Facts for Investors to Verify
- Confirm whether the filing should be attributed to Zeta Acquisition Corp. III rather than Kura Oncology, Inc.
- Verify the company’s shell-company, blank-check status and whether any subsequent business combination occurred.
- Reconcile the $18,217 cash balance with $161,255 of current liabilities and $125,000 of stockholder notes.
- Review the terms, holders, maturity provisions, and related-party nature of the 6% demand notes.
- Assess the going-concern disclosure and the company’s ability to obtain further financing.
- Confirm that the company had generated no revenue since its November 16, 2007 inception and had no identified acquisition target as of the filing.